Ozempic

Ozempic, a semaglutide-based drug (also sold as Wegovy and Rybelsus) by Novo Nordisk, is a GLP-1 receptor agonist used to treat diabetes and obesity. It's newsworthy due to its widespread use, potential side effects, and evolving market dynamics. Recent studies show Wegovy users have a higher risk of sight loss compared to Ozempic users. Analysis suggests these drugs could be manufactured cheaply, potentially increasing accessibility in lower-income countries. Research also indicates GLP-1 medications may help fight addiction. However, Novo Nordisk faces challenges: a next-generation weight-loss drug was deemed 'obsolete,' revenue is projected to drop due to price pressures and patent losses, and concerns arise about unregulated sales in places like Hong Kong. Despite these challenges, the FDA recently approved a pill form of Wegovy, marking a significant advancement in weight-loss medication options. The drug's impact on healthcare and the pharmaceutical industry remains significant.